{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:38:11Z","timestamp":1760150291009,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>We characterized the performance as well as safety of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), deployed in the acute coronary syndrome (ACS) setting. We enrolled patients who were subjected to percutaneous coronary intervention (PCI) between July 2015 and March 2016 and took into consideration demographics, clinical and laboratory data, and clinical outcomes. We defined the primary endpoint as the 48-month rate of major cardiovascular adverse events (MACE), including cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). The secondary endpoints were all-cause death, cardiac death, MI, and TLR rates at 12-, 24-, 36-, and 48 months. We enrolled 232 patients in whom 282 stents were implanted, including 88 ACS and 144 chronic coronary syndrome (CCS) patients. The mean age of the ACS population was 67 \u00b1 13 years old, and 32% of it consisted of females. Patients with ACS were characterized by lower rates of arterial hypertension (85.2% vs. 95.8%, p = 0.004), dyslipidemia (67% vs. 81.9%, p = 0.01), prior MI (34.1% vs. 57.6%, p &lt; 0.001), and prior PCI (35.2% vs. 68.8%, p &lt; 0.001). At 48 months, among the ACS patients, the rates of MACE, death, cardiac death, MI, and TLR were 23.9%, 11.4%, 7.9%, 9.1%, and 10.2%, respectively. No stent thrombosis cases were reported. Multivariable Cox regression revealed that the statistically significant MACE predictors were massive calcifications in coronary arteries (HR 9.0, 95% CI 1.75\u201346.3, p = 0.009), post-dilatation (HR 3.78, 95% CI 1.28\u201311.2, p = 0.016), prior CABG (HR 6.64, 95% CI 1.62\u201327.1, p = 0.008), vitamin K antagonist use (HR 5.99, 95% CI 1.29\u201327.8, p = 0.022), and rivaroxaban use (HR 51.7, 95% CI 4.48\u2013596, p = 0.002). The study findings show that Alex Plus was effective and safe in a contemporary cohort of real-world ACS patients undergoing primary PCI. The outcomes were comparable between the ACS and chronic coronary syndrome patients, with a trend of lower TLR in ACS patients at 4 years.<\/jats:p>","DOI":"10.3390\/jpm13111573","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T02:41:56Z","timestamp":1698979316000},"page":"1573","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent"],"prefix":"10.3390","volume":"13","author":[{"given":"Maciej","family":"Tyczynski","sequence":"first","affiliation":[{"name":"Department of Invasive Cardiology, Centre of Postgraduate Medical Education, 02-507 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kern","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-082 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patryk","family":"Buller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Provincial Integrated Hospital, 09-400 Plock, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Cardiology, State Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-5611","authenticated-orcid":false,"given":"Jacek","family":"Bil","sequence":"additional","affiliation":[{"name":"Department of Invasive Cardiology, Centre of Postgraduate Medical Education, 02-507 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jcin.2015.02.026","article-title":"A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention","volume":"8","author":"Higuma","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"872398","DOI":"10.3389\/fcvm.2022.872398","article-title":"Surgical Turned-Downed CHIP Cases-Can PCI Save the Day?","volume":"9","author":"Achim","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jcin.2020.04.004","article-title":"Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest","volume":"13","author":"Omer","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bil, J., Gil, R.J., Kern, A., Pawlowski, T., Seweryniak, P., and Sliwinski, Z. (2015). Novel sirolimus-eluting stent Prolim(R) with a biodegradable polymer in the all-comers population: One year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovasc. Disord., 15.","DOI":"10.1186\/s12872-015-0139-5"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: Results from a registry of 18,334 patients","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Canfield, J., and Totary-Jain, H. (2018). 40 Years of Percutaneous Coronary Intervention: History and Future Directions. J. Pers. Med., 8.","DOI":"10.3390\/jpm8040033"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jjcc.2016.02.012","article-title":"Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trial","volume":"69","author":"Liu","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gherasie, F.A., Valentin, C., and Busnatu, S.S. (2023). Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?. J. Pers. Med., 13.","DOI":"10.3390\/jpm13050753"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Leone, A., Simonetti, F., Avvedimento, M., Angellotti, D., Immobile Molaro, M., Franzone, A., Esposito, G., and Piccolo, R. (2022). Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091378"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Schmidt, T., and Abbott, J.D. (2018). Coronary Stents: History, Design, and Construction. J. Clin. Med., 7.","DOI":"10.3390\/jcm7060126"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jezewski, M.P., Kubisa, M.J., Eyileten, C., De Rosa, S., Christ, G., Lesiak, M., Indolfi, C., Toma, A., Siller-Matula, J.M., and Postula, M. (2019). Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122167"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.4244\/EIJ-D-22-00300","article-title":"In vitro effect of intravascular lithotripsy on the polymer of a drug-eluting stent","volume":"18","author":"Achim","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tyczy\u0144ski, M., Kern, A., Buller, P., Wa\u0144ha, W., Gil, R.J., and Bil, J. (2023). Clinical Outcomes and Prognostic Factors in Complex, High-Risk Indicated Procedure (CHIP) and High-Bleeding-Risk (HBR) Patients Undergoing Percutaneous Coronary Intervention with Sirolimus-Eluting Stent Implantation: 4-Year Results. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165313"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5603\/CJ.2016.0108","article-title":"Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model","volume":"23","author":"Buszman","year":"2016","journal-title":"Cardiol. J."},{"key":"ref_18","first-page":"187","article-title":"Short-term healing response after implantation of the thin-strut, fast-releasing sirolimus-eluting biodegradable polymer-coated Alex Plus stent: Optical coherence tomography study","volume":"16","author":"Dobrolinska","year":"2020","journal-title":"Postepy Kardiol. Interwencyjnej"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/01.CIR.78.2.486","article-title":"Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology\/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty)","volume":"78","author":"Ryan","year":"1988","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(13)60108-7","article-title":"Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: Development and validation of SYNTAX score II","volume":"381","author":"Farooq","year":"2013","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lancellotti, P., Zamorano, J., Habib, G., and Badano, L. (2016). The EACVI Textbook of Echocardiography, Oxford University Press.","DOI":"10.1093\/med\/9780198726012.001.0001"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12928-022-00842-6","article-title":"Preferable vascular healing of ultrathin strut biodegradable-polymer sirolimus-eluting stents in patients with acute coronary syndrome","volume":"37","author":"Kawamura","year":"2022","journal-title":"Cardiovasc. Interv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12928-022-00862-2","article-title":"Early vascular healing of ultra-thin strut polymer-free sirolimus-eluting stents in acute coronary syndrome: USUI-ACS study","volume":"38","author":"Matsuhiro","year":"2023","journal-title":"Cardiovasc. Interv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1253\/circj.CJ-14-1000","article-title":"Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome -HATTRICK-OCT trial","volume":"79","author":"Karjalainen","year":"2015","journal-title":"Circ. J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iannaccone, M., Barbero, U., De Benedictis, M., Imori, Y., Quadri, G., Trabattoni, D., Ryan, N., Venuti, G., Montabone, A., and Wojakowski, W. (2020). Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study). BMC Cardiovasc. Disord., 20.","DOI":"10.1186\/s12872-020-01420-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ccd.29468","article-title":"Differential impact of abluminal groove-filled biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent on and off dual antiplatelet therapy","volume":"99","author":"Saito","year":"2022","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.123.065448","article-title":"Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial","volume":"148","author":"Valgimigli","year":"2023","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e20220594","DOI":"10.36660\/abc.20220594","article-title":"Real-World Assessment of an Ultrathin Strut, Sirolimus-Eluting Stent in Patients with ST-Elevation Myocardial Infarction Submitted to Primary Percutaneous Coronary Intervention (INSTEMI Registry)","volume":"120","author":"Araujo","year":"2023","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.carrev.2016.04.001","article-title":"A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy","volume":"17","author":"Jimenez","year":"2016","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.carrev.2021.02.008","article-title":"Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial","volume":"34","author":"Iglesias","year":"2022","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10557-021-07258-z","article-title":"Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: The PRAGUE-22 Study","volume":"36","author":"Tousek","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e007331","DOI":"10.1161\/CIRCINTERVENTIONS.118.007331","article-title":"Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients","volume":"11","author":"Roguin","year":"2018","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00392-022-01994-4","article-title":"Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: An analysis from the randomized BIOFLOW trials","volume":"111","author":"Hemetsberger","year":"2022","journal-title":"Clin. Res. Cardiol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:16:21Z","timestamp":1760130981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jpm13111573"],"URL":"https:\/\/doi.org\/10.3390\/jpm13111573","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}